CClinicalTrials.gg
CompletedNCT03533374CIEDUpdated Jul 22, 2020Results posted

Validation of Criteria for Identification of Epileptiform Discharges in EEG Recordings of Patients With Epilepsy

An observational study in Epilepsy and Non-Epileptic Seizure, sponsored by Sándor Beniczky. Completed. Per ClinicalTrials.gov, last updated 2020-07-22.

Sponsored by Sándor Beniczky · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
100
Sex
All
01

Study summary

Electroencephalography (EEG) records electric activity of the brain using electrodes placed on the scalp. EEG is an important tool in the diagnostic work-up of patients with epilepsy. Specific types of sharp EEG discharges (epileptiform discharges) are associated with patients with epilepsy.

The International Federation of Clinical Neurophysiology (IFCN) has recently published a set of six operational criteria for identifying epileptiform discharges. At least four criteria need to be present in order to classify a discharge as epileptiform. These criteria are largely based on expert opinion and have not been validated yet. It is not clear what the sensitivity and specificity of these criteria are, and which combination of these criteria are optimal. Each criterion is based on visual assessment. However, it is not known what the inter-rater agreement of these criteria are.

EEG is traditionally inspected in sensor space, i.e. in the recording channels. Advances in signal analysis made possible reconstructing the electric currents in the regions of the brain generating them, and displaying the signals in the source space, instead of the sensor space.

The objectives of this study are: to determine the inter-rater agreement of the IFCN criteria by visual analysis in sensor space, to determine the combination of criteria with the best accuracy (sensitivity and specificity) and assess the accuracy of evaluating the discharges in source space.

The raters will analyze EEG recordings from 100 patients, from two groups: consecutive patients with epilepsy and consecutive patients with non-epileptic paroxysmal episodes. EEG was recorded during long-term video-EEG monitoring. As reference standard, the investigators used the evaluation of the patients´ habitual clinical episode. The performance of the criteria in sensor-space and the analysis in source space will be compared with the unrestricted expert scorings.

Read the detailed description

Epilepsy affects 50 million people of all ages. It is the most common neurologic disorder across the lifespan, and has been found to be associated with an increased risk of mortality compared to the general population.

EEG is an important tool in the diagnostic work-up of patients with suspected epilepsy. The presence of epileptiform EEG discharges (EDs) confirm the diagnosis and provides important information that helps in classifying epilepsy.

EDs are visually identified by experts with training in reading EEG. Although EDs were defined in the previous edition of the IFCN glossary of terms, that definition was conceptual, and the inter-rater agreement for identifying EDs was only moderate. Recently, the IFCN suggested the following operational definition for EDs: Transients distinguishable from background activity with a characteristic morphology; EDs have to fulfill at least 4 of the following 6 criteria:

  1. Di- or tri-phasic waves with sharp or spiky morphology (i.e. pointed peak).
  2. Different wave-duration than the ongoing background activity: either shorter or longer.
  3. Asymmetry of the waveform: a sharply rising ascending phase and a more slowly decaying descending phase, or vice versa.
  4. The transient is followed by an associated slow after-wave.
  5. The background activity surrounding epileptiform discharges is disrupted by the presence of the epileptiform discharges.
  6. Distribution of the negative and positive potentials on the scalp suggests a source of the signal in the brain, corresponding to a radial, oblique or tangential orientation of the source. This is best assessed by inspecting voltage maps constructed using common-average reference.

However, these criteria are largely based on expert opinion. Data from clinical validation studies are lacking, thus it is not known what the sensitivity and specificity of these methods are. The threshold of four fulfilled criteria was arbitrary, and it is not sure whether it yields the optimal accuracy (sensitivity and specificity). Furthermore, since each criterion is based on visual evaluation, it is not known whether all experts would reach the same conclusion.

The IFCN criteria were developed for identifying EDs using the traditional way of inspecting EEG, in the channels of the recording electrodes (sensor space). However, advances in signal analysis made possible to reproduce the electric currents in the brain regions, using a spatial filtering method (source space).

The objective of this study are:

  1. To determine the inter-rater agreement for the IFCN criteria
  2. To determine the number of criteria and their combination that yields the highest diagnostic accuracy
  3. To determine the accuracy of identifying EDs in source space. Raters with experience in clinical EEG will inspect 100 anonymized EEG samples, from consecutive patients with epilepsy and consecutive patients with non-epileptic paroxysmal episodes. All 100 patients have a reference standard for their condition, derived from analysis of their video-EEG recordings of their habitual clinical episode. Patients with both focal and generalized epilepsy, as well as non-epileptic paroxysmal episodes (psychogenic non-epileptic seizures, sleep-disorders, movement disorders, convulsive syncope) are included.

Each EEG sample contains a sharp transient that is either epileptiform or not. EEGs were recoded using the IFCN electrode array of 25 electrodes (including the ones in the inferior temporal chain).

The samples were randomized twice, resulting in two series containing the same set of 100 samples, though with different codes and in different order of presentation. The raters will inspect the two series separately. In the first session the raters will inspect samples in sensor space, using traditional EEG montages (longitudinal and transversal bipolar; common average) and voltage maps. For each sample, they will score the presence or absence of each IFCN criterion. In the second session, the raters will inspect the EEG samples in source space and voltage maps, and will conclude on the presence / absence of EDs.

The performance of these methods will be compared with unrestricted scorings based on the experts´ evaluation.

02

Conditions studied

  • Epilepsy
  • Non-Epileptic Seizure

Keywords

  • Accuracy
  • Inter-ictal EEG Discharges
  • Inter-rater agreement
  • Long Term Monitoring
  • Sensitivity
  • Sharp transients
  • Specificity
  • Source Space
  • Voltage maps
03

In context

Epilepsy

1,806 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

This study's enrollment of 100 is close to the median of 102 across 521 observational studies indexed under Epilepsy.

Browse Epilepsy studies →

Lead sponsor

Sándor Beniczky is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with epilepsy and patient with non-epileptic seizures (paroxysmal episodes)

Inclusion criteria

  1. Patients who underwent long-term video-EEG monitoring
  2. Patients who had at least one habitual episode (seizure) recorded on video and EEG.
  3. Patients with sharp transients.
  4. For patients with epilepsy: the interictal (epileptiform) sharp transients are concordant with the ictal recording

Exclusion criteria

Exclusion Criteria:

Patients with both epileptic seizures and non-epileptic seizures (paroxysmal episodes).

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
100 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with epileptic seizures

    Electroencephalogram (EEG) and visual evaluation - Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians).

    Diagnostic Test: Electroencephalogram (EEG) and visual evaluation

  • Patients with non-epileptic seizures

    Electroencephalogram (EEG) and visual evaluation - Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians).

    Diagnostic Test: Electroencephalogram (EEG) and visual evaluation

Interventions

  • Diagnostic testElectroencephalogram (EEG) and visual evaluation

    Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians).

06

What researchers measure

Primary outcomes

  1. Inter-rater Agreement of the International Federation of Clinical Neurophysiology (IFCN) Criteria (Cut-off=4) in Sensor Space and of Detection of Epileptiform Discharges (EDs) in Source Space

    Inter-rater agreement of IFCN criteria (cut-off=4) in sensor space and of detection of EDs in source space was calculated using Gwet´s Agreemen Coefficient (AC1). We calculated Gwet's coefficients of agreement AC1 for beyond chance agreement, because, compared with Cohen's Kappa, the Gwet's agreement coefficient is less affected by prevalence and marginal probability and thereby avoids the problem known as the "paradoxes of kappa". Strength of agreement beyond chance was interpreted according to Landis and Koch criteria: poor (\<0), slight (0·01-0·20), fair (0·21-0·40), moderate (0·41-0·60), substantial (0·61-0·80), and almost perfect (0·81-1·00).

    Time frame: 1 year

  2. Sensitivity and Specificity IFCN Criteria (Cut-off=4)

    This is a diagnostic study, hence sensitivity and specificity must be calculated from different groups: sensitivity form the group of patients with epilepsy and specificity from the gruoup of patients who do not have epilepsy. Sensitivity: the percentage of patients with abnormal index test (true positives) among patients with epilepsy. Specificity: the percentage of patients with normal index test (true negatives) among patients who do not have epilepsy.

    Time frame: 1 year

  3. The Sensitivity and Specificity of Detecting EDs in Source-space

    This is a diagnostic study, hence sensitivity and specificity must be calculated from different groups: sensitivity form the group of patients with epilepsy and specificity from the group of patients who do not have epilepsy. Sensitivity: the percentage of patients with abnormal index test (true positives) among patients with epilepsy. Specificity: the percentage of patients with normal index test (true negatives) among patients who do not have epilepsy.

    Time frame: 1 year

07

Results

Posted Jul 22, 2020

Participant flow

Participant flow — Overall Study
MilestonePatients With Epileptic SeizuresPatients With Non-epileptic Seizures
Started5446
Completed5446
Not completed00

Outcome measures

PrimaryInter-rater Agreement of the International Federation of Clinical Neurophysiology (IFCN) Criteria (Cut-off=4) in Sensor Space and of Detection of Epileptiform Discharges (EDs) in Source Space

Inter-rater agreement of IFCN criteria (cut-off=4) in sensor space and of detection of EDs in source space was calculated using Gwet´s Agreemen Coefficient (AC1). We calculated Gwet's coefficients of agreement AC1 for beyond chance agreement, because, compared with Cohen's Kappa, the Gwet's agreement coefficient is less affected by prevalence and marginal probability and thereby avoids the problem known as the "paradoxes of kappa". Strength of agreement beyond chance was interpreted according to Landis and Koch criteria: poor (\<0), slight (0·01-0·20), fair (0·21-0·40), moderate (0·41-0·60), substantial (0·61-0·80), and almost perfect (0·81-1·00).

Time frame:
1 year
Reported as:
Number · AC1 - agreement coefficient
Inter-rater Agreement of the International Federation of Clinical Neurophysiology (IFCN) Criteria (Cut-off=4) in Sensor Space and of Detection of Epileptiform Discharges (EDs) in Source Space
AC1 - agreement coefficientPatients With Epileptic SeizuresPatients With Non-epileptic Seizures
Inter-rater Agreement of the International Federation of Clinical Neurophysiology (IFCN) Criteria (Cut-off=4) in Sensor Space and of Detection of Epileptiform Discharges (EDs) in Source Space0.61 (0.53 to 0.69)0.59 (0.51 to 0.68)
PrimarySensitivity and Specificity IFCN Criteria (Cut-off=4)

This is a diagnostic study, hence sensitivity and specificity must be calculated from different groups: sensitivity form the group of patients with epilepsy and specificity from the gruoup of patients who do not have epilepsy. Sensitivity: the percentage of patients with abnormal index test (true positives) among patients with epilepsy. Specificity: the percentage of patients with normal index test (true negatives) among patients who do not have epilepsy.

Time frame:
1 year
Reported as:
Number · percentage
Sensitivity and Specificity IFCN Criteria (Cut-off=4)
percentagePatients With Epileptic SeizuresPatients With Non-epileptic Seizures
Sensitivity and Specificity IFCN Criteria (Cut-off=4)96.3 (87.3 to 99.6)84.8 (71.1 to 93.7)
PrimaryThe Sensitivity and Specificity of Detecting EDs in Source-space

This is a diagnostic study, hence sensitivity and specificity must be calculated from different groups: sensitivity form the group of patients with epilepsy and specificity from the group of patients who do not have epilepsy. Sensitivity: the percentage of patients with abnormal index test (true positives) among patients with epilepsy. Specificity: the percentage of patients with normal index test (true negatives) among patients who do not have epilepsy.

Time frame:
1 year
Reported as:
Number · percentage
The Sensitivity and Specificity of Detecting EDs in Source-space
percentagePatients With Epileptic SeizuresPatients With Non-epileptic Seizures
The Sensitivity and Specificity of Detecting EDs in Source-space85.2 (72.9 to 93.4)95.7 (85.2 to 99.5)

Adverse events

Collected over Adverse Events were not monitored/assessed. Not applicable - this is a non-invasive diagnostic test.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients With Epileptic Seizures———
Patients With Non-epileptic Seizures———

Baseline characteristics

Age, Continuous
Age, Continuous(years)Patients With Epileptic SeizuresPatients With Non-epileptic SeizuresTotal
Mean32.5 ± 18.937.6 ± 19.734.8 ± 19.3
Sex: Female, Male
Sex: Female, Male(Participants)Patients With Epileptic SeizuresPatients With Non-epileptic SeizuresTotal
Female253560
Male291140
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Patients With Epileptic SeizuresPatients With Non-epileptic SeizuresTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5446100
More than one race000
Unknown or Not Reported000
08

Study locations

No study locations are listed for this record.

09

References and documents

Study documents

  • Study protocol · Dec 31, 2018

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03533374
Lead sponsor
Sándor Beniczky
Collaborators
Aarhus University Hospital, Central Denmark Region, Filadelfia Epilepsy Hospital, University Health Network, Toronto, University Hospital Erlangen, Oslo University Hospital
Responsible party
Sándor Beniczky (professor, Aarhus University Hospital) — Sponsor-investigator
First posted
May 23, 2018
Start date
Jan 1, 2012
Primary completion
Jan 1, 2018
Completion
Jan 1, 2018
Results posted
Jul 22, 2020
Last update
Jul 22, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion